Altrius Capital Management Inc Acquires 12,646 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Altrius Capital Management Inc increased its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 6.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 224,804 shares of the company’s stock after purchasing an additional 12,646 shares during the period. Roche accounts for 2.0% of Altrius Capital Management Inc’s holdings, making the stock its 12th biggest holding. Altrius Capital Management Inc’s holdings in Roche were worth $7,794,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Archer Investment Corp boosted its position in Roche by 10.6% during the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares in the last quarter. Rhumbline Advisers grew its position in shares of Roche by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 103,985 shares of the company’s stock worth $3,605,000 after buying an additional 904 shares during the last quarter. Waldron Private Wealth LLC bought a new position in shares of Roche during the 2nd quarter worth approximately $263,000. Hantz Financial Services Inc. purchased a new stake in Roche during the second quarter valued at approximately $1,164,000. Finally, Lee Danner & Bass Inc. purchased a new position in Roche in the second quarter worth $327,000.

Roche Stock Up 0.7 %

OTCMKTS RHHBY opened at $39.61 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04. The stock’s fifty day moving average price is $39.89 and its 200 day moving average price is $34.97. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $42.43.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RHHBY. The Goldman Sachs Group began coverage on Roche in a report on Thursday, May 30th. They set a “sell” rating for the company. Deutsche Bank Aktiengesellschaft cut Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, Bank of America upgraded Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Roche has a consensus rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.